Analysts expect Invuity Inc (NASDAQ:IVTY) to post $11.47 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Invuity’s earnings. The lowest sales estimate is $11.00 million and the highest is $11.86 million. Invuity posted sales of $9.60 million during the same quarter last year, which would indicate a positive year over year growth rate of 19.5%. The business is expected to announce its next earnings results on Tuesday, November 6th.

On average, analysts expect that Invuity will report full-year sales of $45.86 million for the current fiscal year, with estimates ranging from $45.00 million to $46.40 million. For the next year, analysts expect that the firm will post sales of $55.86 million, with estimates ranging from $54.00 million to $58.30 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that follow Invuity.

Invuity (NASDAQ:IVTY) last issued its earnings results on Thursday, August 2nd. The medical instruments supplier reported ($0.37) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.10. Invuity had a negative net margin of 89.29% and a negative return on equity of 724.87%. The business had revenue of $10.50 million for the quarter, compared to analyst estimates of $10.73 million.

IVTY has been the topic of several research reports. Zacks Investment Research upgraded shares of Invuity from a “hold” rating to a “buy” rating and set a $4.25 price objective on the stock in a report on Thursday, July 5th. ValuEngine downgraded shares of Invuity from a “hold” rating to a “sell” rating in a report on Thursday, September 6th. William Blair downgraded shares of Invuity from an “outperform” rating to a “market perform” rating in a report on Tuesday, September 11th. Piper Jaffray Companies downgraded shares of Invuity from an “overweight” rating to a “neutral” rating in a report on Tuesday, September 11th. Finally, Stifel Nicolaus downgraded shares of Invuity from a “buy” rating to a “hold” rating in a report on Tuesday, September 11th. Six analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Invuity currently has a consensus rating of “Hold” and a consensus target price of $6.81.

IVTY opened at $7.40 on Thursday. The company has a debt-to-equity ratio of 10.57, a quick ratio of 1.69 and a current ratio of 2.13. Invuity has a 1-year low of $2.35 and a 1-year high of $9.55. The firm has a market cap of $178.15 million, a price-to-earnings ratio of -3.36 and a beta of 0.01.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Fondren Management LP acquired a new position in Invuity during the second quarter worth $168,000. Northern Trust Corp raised its holdings in Invuity by 32.4% during the second quarter. Northern Trust Corp now owns 45,244 shares of the medical instruments supplier’s stock worth $176,000 after buying an additional 11,073 shares during the last quarter. Spark Investment Management LLC raised its holdings in Invuity by 138.2% during the second quarter. Spark Investment Management LLC now owns 45,500 shares of the medical instruments supplier’s stock worth $177,000 after buying an additional 26,400 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Invuity by 5,196.9% during the first quarter. JPMorgan Chase & Co. now owns 47,672 shares of the medical instruments supplier’s stock worth $184,000 after buying an additional 46,772 shares during the last quarter. Finally, BlackRock Inc. raised its holdings in shares of Invuity by 43.4% in the second quarter. BlackRock Inc. now owns 56,511 shares of the medical instruments supplier’s stock valued at $221,000 after purchasing an additional 17,091 shares during the last quarter. Hedge funds and other institutional investors own 59.95% of the company’s stock.

Invuity Company Profile

Invuity, Inc, a medical technology company, develops and markets surgical devices in the United States and Asia. The company through its intelligent photonics technology platform develops single-use and reusable illuminated surgical devices, which provide surgeons with illumination and direct visualization of surgical cavities.

Featured Article: Diversification Important in Investing

Get a free copy of the Zacks research report on Invuity (IVTY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Invuity (NASDAQ:IVTY)

Receive News & Ratings for Invuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity and related companies with MarketBeat.com's FREE daily email newsletter.